相似文献
1
Straight to the heart: Pleiotropic antiarrhythmic actions of oral anticoagulants.
Pharmacol Res. 2019 Jul;145:104257. doi: 10.1016/j.phrs.2019.104257. Epub 2019 May 2.
2
Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants.
Cardiovasc Res. 2014 Mar 1;101(3):344-51. doi: 10.1093/cvr/cvt343. Epub 2014 Jan 2.
3
New drugs for atrial fibrillation.
J Interv Card Electrophysiol. 2008 Oct;23(1):15-21. doi: 10.1007/s10840-008-9278-2. Epub 2008 Jun 6.
4
New and emerging antiarrhythmic and anticoagulant agents for atrial fibrillation.
Am J Health Syst Pharm. 2010 May 1;67(9 Suppl 5):S26-34. doi: 10.2146/ajhp100154.
5
Atrial fibrillation and human immunodeficiency virus type-1 infection: a systematic review. Implications for anticoagulant and antiarrhythmic therapy.
Br J Clin Pharmacol. 2019 Mar;85(3):508-515. doi: 10.1111/bcp.13837. Epub 2019 Jan 11.
6
Stroke prevention in atrial fibrillation: impact of novel oral anticoagulants.
Clin Appl Thromb Hemost. 2013 Jun;19(3):241-8. doi: 10.1177/1076029612458148. Epub 2012 Sep 4.
7
Pharmacologic management of atrial fibrillation: established and emerging options.
J Manag Care Pharm. 2009 Aug;15(6 Suppl B):S10-8.
8
A new landscape for stroke prevention in atrial fibrillation: focus on new anticoagulants, antiarrhythmic drugs, and devices.
Stroke. 2011 Nov;42(11):3316-22. doi: 10.1161/STROKEAHA.111.617886. Epub 2011 Oct 13.
9
[Update on current care guideline: atrial fibrillation].
Duodecim. 2014;130(12):1194-6.
10
Will warfarin soon be passé? New approaches to stroke prevention in atrial fibrillation.
J Cardiovasc Pharmacol. 2008 Jul;52(1):18-27. doi: 10.1097/FJC.0b013e318177e1f2.
引用本文的文献
1
Thrombin receptor PAR4 cross-activates the tyrosine kinase c-met in atrial cardiomyocytes.
Naunyn Schmiedebergs Arch Pharmacol. 2025 Mar;398(3):2783-2796. doi: 10.1007/s00210-024-03436-6. Epub 2024 Sep 16.
2
The thrombin receptor PAR4 supports visceral adipose tissue inflammation.
Naunyn Schmiedebergs Arch Pharmacol. 2024 Sep;397(9):7187-7200. doi: 10.1007/s00210-024-03097-5. Epub 2024 Apr 23.
3
Pathophysiology and clinical relevance of atrial myopathy.
Basic Res Cardiol. 2024 Apr;119(2):215-242. doi: 10.1007/s00395-024-01038-0. Epub 2024 Mar 12.
4
Prophylactic rivaroxaban in the early post-discharge period reduces the rates of hospitalization for atrial fibrillation and incidence of sudden cardiac death during long-term follow-up in hospitalized COVID-19 survivors.
Front Pharmacol. 2023 May 30;14:1093396. doi: 10.3389/fphar.2023.1093396. eCollection 2023.
5
Interaction of Cardiovascular Nonmodifiable Risk Factors, Comorbidities and Comedications With Ischemia/Reperfusion Injury and Cardioprotection by Pharmacological Treatments and Ischemic Conditioning.
Pharmacol Rev. 2023 Jan;75(1):159-216. doi: 10.1124/pharmrev.121.000348. Epub 2022 Dec 8.
6
Direct oral anticoagulation and severe obesity - One size fits all?
Int J Cardiol Heart Vasc. 2021 Dec 6;37:100923. doi: 10.1016/j.ijcha.2021.100923. eCollection 2021 Dec.
7
Stroke prevention of atrial fibrillation: Improving geographic under-use of contemporary antithrombotic approaches remains a challenge.
Int J Cardiol Heart Vasc. 2021 Apr 23;34:100785. doi: 10.1016/j.ijcha.2021.100785. eCollection 2021 Jun.
8
Natural history of COVID-19 and current knowledge on treatment therapeutic options.
Biomed Pharmacother. 2020 Sep;129:110493. doi: 10.1016/j.biopha.2020.110493. Epub 2020 Jul 3.
9
Anticoagulant and antiarrhythmic effects of heparin in the treatment of COVID-19 patients.
J Thromb Haemost. 2020 Aug;18(8):2073-2075. doi: 10.1111/jth.14902.
10
Breaking bad: Higher risk of osteoporosis with vitamin K antagonists compared to direct oral anticoagulants in patients with atrial fibrillation.
Int J Cardiol Heart Vasc. 2020 Apr 10;27:100487. doi: 10.1016/j.ijcha.2020.100487. eCollection 2020 Apr.
本文引用的文献
1
Postoperative atrial fibrillation: mechanisms, manifestations and management.
Nat Rev Cardiol. 2019 Jul;16(7):417-436. doi: 10.1038/s41569-019-0166-5.
2
The role of PLC-IP3 cascade on 4-aminopyridine (4-AP) contracture in electrically-driven rat atrial and diaphragmatic strips: new evidence by neomycin and heparin.
Cell Mol Biol (Noisy-le-grand). 2018 Oct 30;64(13):26-32.
3
Profibrotic, Electrical, and Calcium-Handling Remodeling of the Atria in Heart Failure Patients With and Without Atrial Fibrillation.
Front Physiol. 2018 Oct 9;9:1383. doi: 10.3389/fphys.2018.01383. eCollection 2018.
4
Role of inflammatory signaling in atrial fibrillation.
Int J Cardiol. 2019 Jul 15;287:195-200. doi: 10.1016/j.ijcard.2018.10.020. Epub 2018 Oct 4.
5
Antiarrhythmic drugs for atrial fibrillation: Imminent impulses are emerging.
Int J Cardiol Heart Vasc. 2018 Sep 13;21:11-15. doi: 10.1016/j.ijcha.2018.08.005. eCollection 2018 Dec.
6
Factor Xa inhibition by rivaroxaban regulates fibrogenesis in human atrial fibroblasts with modulation of nitric oxide synthesis and calcium homeostasis.
J Mol Cell Cardiol. 2018 Oct;123:128-138. doi: 10.1016/j.yjmcc.2018.09.003. Epub 2018 Sep 10.
7
Cardiomyocyte Inflammasome Signaling in Cardiomyopathies and Atrial Fibrillation: Mechanisms and Potential Therapeutic Implications.
Front Physiol. 2018 Aug 13;9:1115. doi: 10.3389/fphys.2018.01115. eCollection 2018.
8
Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease.
N Engl J Med. 2018 Oct 4;379(14):1332-1342. doi: 10.1056/NEJMoa1808848. Epub 2018 Aug 27.
9
Attenuation of type-1 diabetes-induced cardiovascular dysfunctions by direct thrombin inhibitor in rats: a mechanistic study.
Mol Cell Biochem. 2019 Jan;451(1-2):69-78. doi: 10.1007/s11010-018-3394-9. Epub 2018 Jul 3.
10
Heparin Oligosaccharides Have Antiarrhythmic Effect by Accelerating the Sodium-Calcium Exchanger.
Front Cardiovasc Med. 2018 Jun 7;5:67. doi: 10.3389/fcvm.2018.00067. eCollection 2018.
Zotero 插件